Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
Vincent D. de Jager, Wim Timens, Arnaud Bayle et al. · The Lancet Regional Health - Europe · 2024
In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the need for predictive molecular tests to identify patients eligible for targeted therapy. This review provides an overview of the development and current application of targeted therapies and predictive biomarker testing in European patients with advanced stage NSCLC. Using data from eleven European countries, we conclude that recommendations for predictive testing are incorporated in national guidelines across Europe, although there are differences in their comprehensiveness. Moreover, the availability of recently EMA-approved targeted therapies varies between European countries. Unfortunately, routine assessment of national/regional molecular testing rates is limited. As a result, it remains uncertain which proportion of patients with metastatic NSCLC in Europe receive adequate predictive biomarker testing. Lastly, Molecular Tumor Boards (MTBs) for discussion of molecular test results are widely implemented, but national guidelines for their composition and functioning are lacking. The establishment of MTB guidelines can provide a framework for interpreting rare or complex mutations, facilitating appropriate treatment decision-making, and ensuring quality control.
Cited by 51 works. doi:10.1016/j.lanepe.2024.100838
Authors
- Vincent D. de Jager
- Wim Timens
- Arnaud Bayle
- Johan Botling
- Luka Brčić
- Reinhard Büttner
- Libor Havel
- Maximilian Johannes Hochmair
- Paul M Hofman
- Annelies Janssens
- Mikael Johansson
- Léon C.L.T. van Kempen
- Izidor Kern
- Fernando López‐Ríos
- Margreet Lüchtenborg
- José Carlos Machado
- Katja Mohorčič
- Luis G Paz-Ares
- Sanjay Popat
References
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- Drugging the undruggable RAS: Mission Possible?
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation